0
Medibiofarma announces the nomination of a second Development Candidate
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound will start IND enabling studies the second quarter 2019.
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound will start IND enabling studies the second quarter 2019.
Compound MBF-118, a novel PPAR-γ receptor modulator for the treatment of cancer. The compound will start IND enabling studies the second quarter 2018.